Navigation Links
Pivotal national trial uses newest interventional radiology treatment to bust blood clots in legs
Date:9/15/2008

FAIRFAX, Va.ATTRACTthe first major national trial of a catheter-based treatment for deep vein thrombosiswill evaluate the use of clot-dissolving drugs in combination with clot removal devices to prevent post-thrombotic syndrome in patients with DVT (the formation of a blood clot in a leg vein). PTS, a common irreversible complication of DVT, causes permanent damage to the veins, resulting in debilitating chronic leg pain, swelling, fatigue and/or skin ulcers. About 25�� percent of DVT patients develop PTS when treated with blood thinners alone. While early treatment with blood thinners is important to prevent a life-threatening pulmonary embolism, blood thinners alone do not dissolve the existing clot, which remains in the leg. Preliminary studies have shown that interventional clot-busting treatments canunlike standard DVT therapyremove clots and have strong potential to prevent PTS. The outcomes of this pivotal multicenter trialto be funded at more than $10 million by the National Institutes of Health's National Heart, Lung and Blood Institute (NHLBI)are likely to change the way DVT is treated in the United States.

"The ATTRACT trial could fundamentally shift the 50-year-old DVT treatment paradigm to one that includes interventional clot removal as an essential element of standard DVT care," said interventional radiologist Suresh Vedantham, M.D., who will lead the trial. "By funding this study, the NHLBI has clearly recognized the strong potential of interventional radiology clot removal treatments for DVT to improve public health," added the associate professor at the Washington University School of Medicine's Mallinckrodt Institute of Radiology in St. Louis, Mo.

ATTRACT (Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis) is a multicenter, randomized trial "that will definitively determine if the newest clot-busting treatment (pharmacomechanical catheter-directed thrombolysis or PCDT) prevents post-thrombotic syndrome in patients with DVT," said Vedantham. PCDT combines the use of a clot-dissolving drug with a catheter-mounted miniature clot removal device, allowing an interventional radiologist to break up the clot and remove it from the vein, restoring blood flow. "PTS is a serious complication of DVT that is under recognized and potentially preventable if we are able to dissolve the clots early, before permanent damage to the vein occurs," he noted. "Established PTS is a lifelong, irreversible condition for which there are no consistently effective treatments. Its prevention is extremely important; however, physicians have historically neglected the prevention of PTS," said Vedantham. "The groundbreaking combination of clot-busting drugs with innovative device technologypioneered by interventional radiologistsnow enables clot removal in a safer and more efficient manner, often in a single procedure session. These advances will greatly increase the use of interventional DVT treatments," added Vedantham.

"This research is critical. The Society of Interventional Radiology Foundation initiated a DVT research consensus panel four years ago, bringing together clinicians and scientists from all disciplines and from all settingsacademia, private practice, government and industryand determining the need for the ATTRACT trial," said Michael Darcy, M.D., chair of the board of directors for SIR Foundation, a scientific foundation dedicated to fostering research and education in interventional radiology. The SIR Foundation has been a critical partner in developing the ATTRACT trial, helping to coordinate the site selection process and partnering with the ATTRACT research team to conduct the trial, said Vedantham.

DVT is the formation of a blood clot, known as a thrombus, in a deep leg vein. This can be a very serious condition that often causes permanent damage to the leg, known as post-thrombotic syndrome. Early treatment with blood thinners is important to prevent a life-threatening pulmonary embolism, but blood thinners do not dissolve the existing clot, which remains in the leg. While many patients' clots will slowly dissolve over time, often the vein wall and vein valves become irreversibly damaged in the process. "PTS develops as a direct result of having the blood clot stay in the vein. The blood clot continues to block the vein and permanently damages its one-way valves, resulting in the pooling of blood in the leg, chronic leg pain, swelling and fatigue and sometimes skin ulcers. It's logical that immediate clot removal will prevent PTS," said Vedantham.

The ATTRACT trialthe first NIH-funded multicenter, randomized trial of any interventional DVT therapywill begin later this year. The trial will assess the presence and severity of PTS, quality of life, relief of pain and swelling, safety and costs. At least 28 U.S. clinical centers will enroll 692 patients and monitor their health for two years, said Vedantham, who is chair of the DVT Research Committee of SIR's Venous Forum and vice chair of the Venous Disease Coalition. The Society of Interventional Radiology is a member of the Venous Disease Coalition.


'/>"/>

Contact: Maryann Verrillo
mverrillo@SIRweb.org
703-460-5572
Society of Interventional Radiology
Source:Eurekalert

Related biology news :

1. Wolves find happy hunting grounds in Yellowstone National Park
2. BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo
3. ESMO International Symposium on Immunology
4. Story tips from the US Department of Energys Oak Ridge National Laboratory, September 2007
5. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
6. Director of National Intelligence to Speak at Conference
7. Singapore National Science and Technology Awards
8. Conservation International and Toyota partner to protect Philippines rain forests
9. International team shows mercury concentrations in fish respond quickly to increased deposition
10. International team shows mercury concentrations in fish respond quickly to increased deposition
11. Office of the Director of National Intelligence, CIO to Speak at Government Security Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
Breaking Biology News(10 mins):
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... ... sources for advanced technology applications, has announced a facility expansion to accommodate its ... 3,000 square feet of new workspace and renovation of the existing areas. The ...
(Date:5/23/2017)... ... May 23, 2017 , ... Customers often prefer ... again and again. METTLER TOLEDO has released two new videos that show how ... integration of the ACT350 into Siemens and Allen Bradley PLCs is easy and ...
(Date:5/21/2017)... ... May 19, 2017 , ... Ovation ... of the American Association of Bioanalysts (AAB) and the College of Reproductive Biology ... conference reinforces AAB’s commitment to excellence in clinical laboratory services and regulations. ...
(Date:5/18/2017)... ... May 18, 2017 , ... Dr. Ralph Mobbs of ... Prince Of Wales Private Hospital. The procedure was performed on a 46-year-old male ... conservative treatments prior to undergoing surgery. , The AxioMed viscoelastic disc is a ...
Breaking Biology Technology: